Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PhRMA’s Marketing Code Touts Sarbanes/Oxley-esque Compliance Mechanism

Executive Summary

The Pharmaceutical Research and Manufacturers of America's revised marketing code will use an executive certification standard similar to Sarbanes-Oxley to assure compliance

You may also be interested in...



PhRMA’s Revised Marketing Code: So Far, So What?

The Pharmaceutical Research and Manufacturers of America's revised marketing code, which went into effect Jan. 1, seems to be going over with - a shrug. Yes, manufacturers are complying and doctors see some changes in long-standing promotion traditions. But the upshot for pharma seems to be, at least from the sales force perspective, so what

PhRMA’s Revised Marketing Code: So Far, So What?

The Pharmaceutical Research and Manufacturers of America's revised marketing code, which went into effect Jan. 1, seems to be going over with - a shrug. Yes, manufacturers are complying and doctors see some changes in long-standing promotion traditions. But the upshot for pharma seems to be, at least from the sales force perspective, so what

Kennedy/Grassley Imports Criminal Liability To Global Drug Safety Efforts

A senior drug company officer or director would be required personally to certify the veracity of product applications and safety submissions to FDA, under Sens. Edward Kennedy, D-Mass., and Chuck Grassley's, R-Iowa, bill to improve safety in global drug manufacturing and distribution

Related Content

UsernamePublicRestriction

Register

LL1125120

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel